JAMA, October 29, 2018Mark R. Trusheim, William M. Cassidy, and Peter B. Bach Drug prices in the United States remain the highest in the world.1 New payment approaches are needed, … Read More
Role of COE networks in curative cellular oncology therapies
COE networks currently play an important role in the delivery of care for specialized service lines, including but not limited to solid organ transplantation (SOT), hematopoietic cell transplantation (HCT) and … Read More
FasterCures joins NEWDIGS Initiative at MIT as a Strategic Partner
Collaboration to drive innovation across healthcare ecosystem CAMBRIDGE, MA, 21 SEPTEMBER 2018–FasterCures, a center of the Milken Institute devoted to saving lives by speeding up and improving the medical research … Read More
Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM)
D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. PharmaExec.com, 2018 After decades of anticipation, 2017 saw the approval of the first of a new generation of durable and … Read More
FoCUS Research Team interviewed for article on Innovating Payment Models
The leads of the FoCUS Research Teams, Strategic Director Mark Trusheim, Research Advisor Casey Quinn, Director of Simulation & Policy Research Daniel Mytelka, and Director of Drug Development Pipeline Research … Read More
Designing financial solutions to ensure affordable access to cures
The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More
FoCUS responds to HHS “Blueprint” Request for Information
Federal initiative seeks to make access to innovative therapies wider and more financially sustainable On May 16, 2018 the US Department of Health and Human Services (HHS) published a … Read More
Stop-Loss Insurance or Reinsurance for Multiyear Contracts
In previous Research Briefs, we have discussed challenges faced by payers when contemplating using multiyear performance-based contracts. In this brief, we extend the discussion to include additional difficulties that may … Read More
Impact of Patient Mobility on Annuity/Performance-Based Contracting
Spreading payments over time for durable or curative therapies can provide a better alignment between benefits and costs, but creates challenges when patients switch insurance coverage during the contract term. … Read More
Orphan Reinsurer Benefit Managers (ORBMs)
An Orphan Reinsurer Benefit Manager (ORBM) could address the financial challenges (payment timing, therapeutic performance risk, actuarial risk), created by durable/potentially curable gene and cell therapies especially for smaller insurers … Read More